4.6 Article

Interleukin-21 and tumor necrosis factor- are critical for the development of autoimmune gastritis in mice

Journal

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Volume 28, Issue 6, Pages 982-991

Publisher

WILEY-BLACKWELL
DOI: 10.1111/jgh.12144

Keywords

autoimmune gastritis; autoantibody production; cytokine

Funding

  1. Japanese Government
  2. Astellas Pharma Inc.
  3. Japan Society for the Promotion of Science (JSPS) [20390207, 21229009, 23590973]
  4. Ministry of Health, Labour and Welfare, Japan
  5. Japanese Society of Gastroenterology
  6. Kato Memorial Trust for Nambyo Research
  7. Waksman Foundation of Japan
  8. Grants-in-Aid for Scientific Research [20390207, 23590973] Funding Source: KAKEN

Ask authors/readers for more resources

Background and Aim Autoimmune gastritis (AIG), an organ-specific autoimmune disease, is accompanied by achlorhydria, pernicious anemia, gastric carcinoid tumors, and gastric cancer. Patients with AIG initially respond to corticosteroids but have a great potential to relapse after treatment is withdrawn. This study examines the roles of cytokines in order to identify potential therapeutic options for AIG patients. Methods Using a mouse model of AIG, we monitored disease progression and administered antibodies in vivo to block cytokines. Results We developed a mouse model of AIG with early onset and rapid progression in which neonatal thymectomy (NTx) was performed on programmed cell death 1-deficient (PD-1/) mice on the BALB/c background. Using NTxPD-1/ mice, we found that in AIG lesions, interferon-, and tumor necrosis factor (TNF)- together with interleukin-21 (IL-21) were highly expressed in the inflamed gastric mucosa. In addition, as with the injection of dexamethasone, in vivo administration of either anti-TNF- or anti-IL-21 suppressed the development of AIG in NTxPD-1/ mice. Conclusions These data reveal the essential role of IL-21 in the development of AIG and suggest that in addition to corticosteroids, anti-TNF- as well as anti-IL-21 have the potential to induce the remission of AIG, offering additional therapeutic options for AIG patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available